CytoDyn Inc.

IMPORTANT CORRECTION OF INVESTIGATIONAL DRUG INFORMATION

On February 11, 2022, CytoDyn, Inc. received a Warning Letter from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion in which FDA asserted that statements made in a video created a misleading impression regarding the safety and efficacy of leronlimab.  Leronlimab is an investigational drug that has not been approved (or authorized) by the U.S. FDA for the treatment of COVID-19 or for any indication.  For more information, click here to access a Dear Healthcare Provider (DHCP) Letter: View Here.

We believe in the future of precision medicine

CytoDyn believes in the future of precision medicine... more specificity, less side effects. Our target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, GvHD, NASH, stroke recovery, multiple sclerosis, COVID-19, NAFLD/NASH, to metastatic cancer. Leronlimab, our CCR5 antagonist, is a once-a-week, subcutaneous injection. One molecule with multiple opportunities.

Welcome to the future of target specific, precision medicine. Welcome to CytoDyn.

We are a biotechnology company focused on developing innovative treatments for multiple therapeutic indications. Our lead candidate leronlimab (PRO 140) belongs to a new class of therapeutics called viral-entry inhibitors and is an experimental monoclonal antibody for HIV treatment.

Leronlimab’s Mechanism of Action for Immuno-oncology

About Our Company

Arrow Down

Leronlimab for HIV

A Fully Humanized Monoclonal Antibody

Leronlimab (PRO 140) is a fully humanized monoclonal antibody directed against CCR5, a molecular portal used by HIV to enter T cells. Leronlimab (PRO 140) blocks the precise sites on CCR5 used by HIV to enter the cell thereby protecting healthy cells from viral entry.

Read More on Leronlimab

CCR5 for Cancer

Developing CCR5 Technology in Cancer Indications

Based on the work of leading oncologists and researchers who played an instrumental role in identifying the role of CCR5 in cancer indications, we continue to explore the role of leronlimab in oncology and have obtained promising results from various pre-clinical studies.

Read More on CCR5

The Science of Developing Monoclonal Antibodies

In the 1980s, a team of scientists developed a technique that fused a common type of tumor cell with a single mouse antibody-producing cell. The resulting hybrid cells all secreted the exact same antibody as the original mouse antibody-producing cell and thus came to be known as monoclonal antibodies. Since then, monoclonal antibodies have come to represent one of the fastest expanding opportunities in the biotechnology/pharma sector.

Learn About Our Science

Latest News

View all news

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

Read More

CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

Read More

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

Read More